Skip to main content

30.06.2018 | Oncology | Ausgabe 11/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2018

Retrospective analysis of primarily treated group D retinoblastoma

Graefe's Archive for Clinical and Experimental Ophthalmology > Ausgabe 11/2018
Hayyam Kiratli, İrem Koç, Onur Inam, Ali Varan, Canan Akyüz
Wichtige Hinweise
Presented in part at the 18th International Society of Ocular Oncology Biennial Conference, March 24-28, 2017, Sydney, Australia.



To assess the effectiveness of intra-arterial chemotherapy (IAC), intravenous chemotherapy (IVC), and their combination in the management of group D retinoblastoma.


This was a retrospective, interventional, comparative, and non-randomized clinical study, including all eyes with primarily treated group D retinoblastoma managed in a single institution from February 2010 to July 2016. Patient demographics, treatment modality (primary enucleation, intravenous chemotherapy, intra-arterial chemotherapy alone or intravenous, and intra-arterial chemotherapy), additional need for consolidation treatments or intravitreal melphalan (IVM) injections, and follow-up time were recorded. The main outcome measure was ocular survival rate after various treatment modalities.


Of 87 eyes of 83 consecutive cases, 9 eyes (10.3%) were primarily enucleated, 37 (42.6%) eyes received IVC, 30 (34.5%) eyes had IAC, and 11 (12.6%) eyes were treated with IVC followed by IAC. After a mean 81.1 ± 75.2 weeks of follow-up, enucleation rates were 56.8% in the IVC group, 23.3% in the IAC group, and 36.6% in the IVC + IAC group (p = 0.021). There was no significant difference of ocular survival estimates among these 3 groups at 2 or 5 years (p = 0.998, p = 0.986). With logistic regression analysis, age; gender; disease laterality; administration of IVM, TTT, or cryotherapy; mean dose of IVM; follow-up time; and number of IAC or IVC cycles were not significantly related to the enucleation rate (p > 0.05 for all variables).


Our experience showed that in group D patients, primary IAC achieved ocular survival in 76.7% of eyes, and less need for local consolidation treatments, whereas following primary IVC ocular survival was 43.2%.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf

Über diesen Artikel

Weitere Artikel der Ausgabe 11/2018

Graefe's Archive for Clinical and Experimental Ophthalmology 11/2018 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

01.08.2020 | DFP-Fortbildung | Ausgabe 4/2020

Konjunktivale Malignome

22.07.2020 | CME | Ausgabe 8/2020

Gender-Medizin in der Augenheilkunde

Der „kleine Unterschied“ zwischen Frauen und Männern

14.07.2020 | original article | Ausgabe 4/2020

Gamma-Knife-Radiochirurgie in der Ophthalmoonkologie